| Ulcerative Colitis
Inflectra vs Omvoh
Side-by-side clinical, coverage, and cost comparison for ulcerative colitis.Deep comparison between: Inflectra vs Omvoh with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOmvoh has a higher rate of injection site reactions vs Inflectra based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Omvoh but not Inflectra, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Inflectra
Omvoh
At A Glance
IV infusion
Every 6-8 weeks
TNF-alpha antagonist
IV infusion / SC injection
Every 4 weeks
IL-23 antagonist
Indications
- Ulcerative Colitis
- Rheumatoid Arthritis
- Ankylosing spondylitis
- Arthritis, Psoriatic
- Psoriasis vulgaris
- Ulcerative Colitis
- Crohn Disease
Dosing
Crohn's Disease, Ulcerative Colitis 5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks; regimen applies to adult and pediatric patients >= 6 years.
Rheumatoid Arthritis 3 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks in combination with methotrexate; may increase up to 10 mg/kg every 8 weeks or as often as every 4 weeks for incomplete response.
Ankylosing spondylitis 5 mg/kg IV at 0, 2, and 6 weeks, then every 6 weeks.
Arthritis, Psoriatic, Psoriasis vulgaris 5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks.
Ulcerative Colitis Induction: 300 mg IV infusion at Weeks 0, 4, and 8; Maintenance: 200 mg SC injection every 4 weeks starting Week 12.
Crohn Disease Induction: 900 mg IV infusion at Weeks 0, 4, and 8; Maintenance: 300 mg SC injection every 4 weeks starting Week 12.
Contraindications
- Doses >5 mg/kg in patients with moderate or severe heart failure
- Previous severe hypersensitivity reaction to infliximab products, inactive ingredients of INFLECTRA, or any murine proteins (including anaphylaxis, hypotension, and serum sickness)
- Previous serious hypersensitivity reaction to mirikizumab-mrkz or any excipient
Adverse Reactions
Most common (>10%) Infections (upper respiratory tract infection, sinusitis, pharyngitis), infusion-related reactions, headache, abdominal pain
Serious Serious infections (pneumonia, cellulitis, abscess, sepsis, tuberculosis, opportunistic infections), malignancies, lymphoma, hepatotoxicity (acute liver failure, autoimmune hepatitis), severe infusion reactions, lupus-like syndrome
Postmarketing Agranulocytosis, neutropenia, interstitial lung disease, Stevens-Johnson Syndrome, toxic epidermal necrolysis, peripheral demyelinating disorders (Guillain-Barre syndrome), acute liver failure, anaphylactic shock, cerebrovascular accidents, leukemia, melanoma, Merkel cell carcinoma
Most common (>=2%) - Ulcerative Colitis Upper respiratory tract infections, injection site reactions, arthralgia, rash, headache, herpes viral infection
Most common (>=5%) - Crohn Disease Upper respiratory tract infections, injection site reactions, headache, arthralgia, elevated liver tests
Serious Intestinal sepsis, listeria sepsis, pneumonia, abscess, cellulitis, sepsis
Pharmacology
Infliximab-dyyb is a chimeric IgG1kappa monoclonal antibody TNF-alpha antagonist that neutralizes the biological activity of TNFalpha by binding with high affinity to soluble and transmembrane forms of TNFalpha, inhibiting receptor binding and downstream proinflammatory cytokine activity in RA, CD, UC, AS, PsA, and Ps.
Mirikizumab-mrkz is a humanized IgG4 monoclonal antibody that selectively binds to the p19 subunit of IL-23, inhibiting its interaction with the IL-23 receptor and suppressing downstream pro-inflammatory cytokine and chemokine release involved in mucosal inflammation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Inflectra
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Omvoh
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Inflectra
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Omvoh
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Inflectra
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Omvoh
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Inflectra Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$5/fillfill
Omvoh Savings Program - Covered benefitCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
InflectraView full Inflectra profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.